GEII-modified liposomes for non-small cell lung cancer targeting: Preparation, ex vitro and in vivo evaluation

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 921-935

  Cheng, Liang ^a   Huang, Fa Zhen ^a,b   Cheng, Li Fang ^a   Zhu, Ya Qin ^a   Hu, Qing ^a   Li, Ling ^a   Wei, Lin ^a   Chen, Da Wei ^a  

^a SOOCHOW UNIVERSITY   (China)

^b Central Hospital of Zaozhuang Minging Group   (China)

Author keywords

Cellular uptake mechanism; Epidermal growth factor receptor; In vivo imaging; Nanosized carrier; Targeted drug delivery

Indexed keywords

DOXORUBICIN; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR; GE11; LIPOSOME; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; GE11 PEPTIDE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL TRANSPORT; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSPORT; ENDOCYTOSIS; EX VIVO STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; TUMOR VOLUME; ZETA POTENTIAL; ACTIVE TRANSPORT; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; K562 CELL LINE; LUNG NEOPLASMS; METABOLISM; NANOMEDICINE; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; K562 CELLS; LIPOSOMES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOMEDICINE; PEPTIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84896887727     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S53310     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Rosell R, Felip E, Garcia-Campelo R, Balana C. The biology of non- small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer. 2004;46:135-148.
3. Harper E, Dang WB, Lapidus RG, Garver RI. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res. 1999;5:4242-4248.
4. Burris HA. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene. 2009;28:S4-S13.
5. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor-tissue. Cancer Res. 1993;53:3765-3770.
6. Xu X, Burgess DJ. Liposomes as carriers for controlled drug delivery. In: Wright J, Burgess DJ, editors. Long Acting Injections and Implants: New York, NY: CRC Press, Springer; 2012.
7. Yu K-F, Zhang W-Q, Luo L-M, et al. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J Nanomedicine. 2013;8:2473-2485.
8. Alexis F, Pridgen E, Langer R, Farokhzad O. Nanoparticle technologies for cancer therapy. Drug Deliv. 2010;197:55-86.
9. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145-160.
10. Drulis-Kawa Z, Dorotkiewicz-Jach A. Liposomes as delivery systems for antibiotics. Int J Pharm. 2010;387:187-198.
11. Vemuri S, Rhodes CT. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv. 1995;70: 95-111.
12. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1:297-315.
13. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615-1626.
14. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148:135-146.
15. Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat. 2005;8:381-402.
16. Benhabbour SR, Luft JC, Kim D, et al. In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor- receptor (EGFR) using a novel heptameric Z (EGFR) domain. J Control Release. 2012;158:63-71.
17. Danesi R, Pasqualetti G, Giovannetti E, et al. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev. 2009;61:408-417.
18. Li ZH, Zhao RJ, Wu XH, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005;19:1978-1985.
19. Master AM, Qi YZ, Oleinick NL, Sen Gupta A. EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies. Nanomedicine. 2012;8: 655-664.
20. Song S, Liu D, Peng J, et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm. 2008;363:155-161.
21. Biswas S, Dodwadkar NS, Deshpande PP, Parab S, Torchilin VP. Surface functionalization of doxorubicin-loaded liposomes with octaarginine for enhanced anticancer activity. Eur J Pharm Biopharm. 2013;84:517-525.
22. Ducat E, Deprez J, Gillet A, et al. Nuclear delivery of a therapeutic peptide by long circulating pH-sensitive liposomes: benefits over classical vesicles. Int J Pharm. 2011;420:319-332.
23. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta. 2001;1513: 207-216.
24. Li J, Li Y, Feng Z-Q, Chen X-G. Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo. Cancer Lett. 2009;279:213-220.
25. Kim IY, Kang YS, Lee DS, et al. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release. 2009;140:55-60.
26. Yang T, Wang Y, Li Z, et al. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine. 2012;8:81-92.
27. Numico G, Castiglione F, Granetto C, et al. Single-agent pegylated liposomal doxorubicin (Caelix (R)) in chemotherapy pretreated non- small cell lung cancer patients: a pilot trial. Lung Cancer. 2002;35: 59-64.
28. Jiang J, Yang S-J, Wang J-C, et al. Sequential treatment of drug- resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm. 2010;76:170-178.
29. Zhou Y, Daryl CD, Zou H, et al. Impact of single-chain fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol. 2007;371:934-947.
30. Li YH, Wang J, Wientjes MG, Au JLS. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev. 2012;64:29-39.
31. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145:182-195.
32. Kuai R, Yuan W, Qin Y, et al. Efficient delivery of payload into tumor cells in a controlled manner by tat and thiolytic cleavable PEG co- modified liposomes. Mol Pharm. 2010;7:1816-1826.
33. Benfer M, Kissel T. Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles. Eur J Pharm Biopharm. 2012;80:247-256.
34. Zhu SJ, Hong MH, Zhang LH, Tang GT, Jiang YY, Pei YY. PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res. 2010;27: 161-174.
35. Oba M, Aoyagi K, Miyata K, et al. Polyplex micelles with cyclic RGD peptide ligands and disulfide cross-links directing to the enhanced transfection via controlled intracellular trafficking. Mol Pharm. 2008;5: 1080-1092.
36. Perumal OP, Inapagolla R, Kannan S, Kannan RM. The effect of surface functionality on cellular trafficking of dendrimers. Biomaterials. 2008;29:3469-3476.
37. Mercer J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol. 2009;11:510-520.
38. Peng SF, Tseng MT, Ho YC, Wei MC, Liao ZX, Sung HW. Mechanisms of cellular uptake and intracellular trafficking with chitosan/DNA/ poly(gamma-glutamic acid) complexes as a gene delivery vector. Biomaterials. 2011;32:239-248.
39. Rappoport JZ. Focusing on clathrin-mediated endocytosis. Biochem J. 2008;412:415-423.
40. Luhmann T, Rimann M, Bitterman AG, Hall H. Cellular uptake and intracellular pathways of PLL-g-PEG-DNA nanoparticles. Bioconjug Chem. 2008;19:1907-1916.
41. Jiang XY, Sha XY, Xin HL, et al. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. Biomaterials. 2011;32:9457-9469.
42. Gao Z, Zhang L, Sun Y. Nanotechnology applied to overcome tumor drug resistance. J Control Release. 2012;162:45-55.